SCHEMBL1709932

SCHEMBL1709932

CC(C)(C)OC(=O)NCc1ncc2n1CCN(Cc1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 1/20 0.45
NPFFR2 Q9Y5X5 1/20 0.45
SIGMAR1 Q99720 3/20 0.44
NAMPT P43490 1/20 0.41
ROCK2 O75116 2/20 0.40
SCD O00767 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GFER P55789 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KMT2A Q03164 1/20 0.39
DRD2 P14416 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
PRKAA2 P54646 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290485 0.85 HTR1A (0.43) PRKAA2
SCHEMBL1709933 0.73 KDM4E (0.44) NAMPTL3MBTL1GFERHSD17B10KMT2A
SCHEMBL5778612 0.72 SIGMAR1 (0.42) SIGMAR1KMT2ALMNAPOLB
SCHEMBL1999832 0.72 SIGMAR1 (0.42) SIGMAR1KMT2AKDM4ELMNAPOLB
SCHEMBL31301273 0.72 DRD2 (0.64) NPFFR1NPFFR2SIGMAR1DRD2
SCHEMBL3440056 0.72 DRD2 (0.64) NPFFR1NPFFR2SIGMAR1DRD2
SCHEMBL5775595 0.71 SIGMAR1 (0.50) SIGMAR1HSD17B10LMNAPOLB
SCHEMBL5772726 0.71 ALDH1A1 (0.48) NPFFR1NPFFR2NAMPTKMT2ADRD2
SCHEMBL1222005 0.71 SIGMAR1 (0.76) NPFFR1NPFFR2SIGMAR1KMT2AKDM4E
SCHEMBL19734921 0.71 SIGMAR1 (0.68) NPFFR1NPFFR2SIGMAR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 NPFFR1 1547/4885NPFFR2 1863/4885SIGMAR1 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.